A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs VX 15 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Proof of concept
  • Acronyms SIGNAL
  • Sponsors Vaccinex
  • Most Recent Events

    • 24 Apr 2017 Based on the data from Cohort A company will design endpoints and group size for continuing Cohort B, as reported in a Vaccinex Media Release.
    • 24 Apr 2017 Preliminary results from Cohort A (n=36) of this trial published in the Vaccinex Media Release
    • 19 Jan 2017 Planned number of patients changed to 116.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top